Latest News and Press Releases

EINDHOVEN, Niederlande, May 16, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), das Medizintechnologieunternehmen, das innovative Rückenmarkstimulationstherapien entwickelt, um die...

ONWARD® Medical Schedules Webcast to Provide Q1 2024 Business Update

EINDHOVEN, Pays-Bas, 03 mai 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext : ONWD), société de technologie médicale à l’origine de thérapies innovantes ciblées sur la restauration du...

ONWARD® Medical Convocation of the 2024 Annual General Meeting of Shareholders and Proposed Resolutions

Dépôt auprès de la FDA d’une demande de classification du dispositif ARC-EX® System basée sur les risques (demande « De Novo ») Levée de fonds de 20 millions d’euros Annonce des résultats...

ONWARD® Medical Reports Full Year 2023 Financial and Operating Results and Shares 2024 Highlights Year-to-Date

ONWARD® Medical Announces Publication of Full Year 2023 Financial Results and Business Update Webcast

Stifel Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 12.00

ONWARD Medical has submitted its De Novo application to the US Food and Drug Administration (FDA) to allow marketing of its breakthrough ARC-EX System.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL....